{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:28:06Z","timestamp":1781656086125,"version":"3.54.5"},"reference-count":42,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["No applicable funding number"],"award-info":[{"award-number":["No applicable funding number"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["Novartis Pharma supports the EuroSpA collaboration"],"award-info":[{"award-number":["Novartis Pharma supports the EuroSpA collaboration"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,6,10]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.<\/jats:p>\n<jats:p>Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0\u201310), for example, pain \u22642\/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \u22642\u2009and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) &lt;1.3 after 6\/12\/24 months of secukinumab treatment were calculated.<\/jats:p>\n<jats:p>Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted\/adjusted for age+sex\/adjusted for multiple confounders).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 1161 secukinumab-treated patients were included (r-axSpA\/nr-axSpA: 922\/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.<\/jats:p>\n<jats:p>During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6\u2009months: pain\u22642: 40%\/28%, OR=1.7; BASDAI\u22642: 37%\/25%, OR=1.8), as were drug retention rates (24\u2009months: 66%\/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%\/8%).<\/jats:p>\n<jats:p>However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Crude remission\/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004166","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T19:02:53Z","timestamp":1721934173000},"page":"e004166","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-9932","authenticated-orcid":false,"given":"Sara Nysom","family":"Christiansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Horskj\u00e6r Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"Ostergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-2840","authenticated-orcid":false,"given":"Brigitte","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-7132","authenticated-orcid":false,"given":"Adrian","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-8482","authenticated-orcid":false,"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7946-1365","authenticated-orcid":false,"given":"Maria Jose","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-9189","authenticated-orcid":false,"given":"Ziga","family":"Rotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-6505","authenticated-orcid":false,"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-3314","authenticated-orcid":false,"given":"Gary J","family":"Macfarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Relas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan K","family":"Wallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-902X","authenticated-orcid":false,"given":"Sella Aarrestad","family":"Provan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Castrejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Zavada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Mogosan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6326-1764","authenticated-orcid":false,"given":"Michael J","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Gitte","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabela","family":"Barcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Erez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja Perdan","family":"Pirkmajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdur","family":"Grondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-7591","authenticated-orcid":false,"given":"Gareth T","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Mari","family":"Hokkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1729","authenticated-orcid":false,"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Vorobjov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Di Giuseppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-3093","authenticated-orcid":false,"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Otero-Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8086-9915","authenticated-orcid":false,"given":"Irene","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-6818","authenticated-orcid":false,"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-6831","authenticated-orcid":false,"given":"Lykke Midtb\u00f8ll","family":"\u00d8rnbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2024072500001072000_10.3.e004166.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2024072500001072000_10.3.e004166.2","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000337","article-title":"Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis","volume":"93","author":"Kilic","year":"2014","journal-title":"Medicine"},{"key":"2024072500001072000_10.3.e004166.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2024072500001072000_10.3.e004166.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2024072500001072000_10.3.e004166.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2024072500001072000_10.3.e004166.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2024072500001072000_10.3.e004166.7","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/rheumatology\/keaa422","article-title":"Non-radiographic versus radiographic axSpA: what\u2019s in a name","volume":"59","author":"Michelena","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024072500001072000_10.3.e004166.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2024072500001072000_10.3.e004166.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"2024072500001072000_10.3.e004166.10","unstructured":"NOVARTIS . Novartis Cosentyx\u00ae gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum, Available: https:\/\/www.novartis.com\/news\/media-releases\/novartis-cosentyx-gains-fourth-indication-eu-first-class-approval-axial-spondyloarthritis-spectrum"},{"key":"2024072500001072000_10.3.e004166.11","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","article-title":"The ASAS-OMERACT core domain set for axial spondyloarthritis","volume":"51","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2024072500001072000_10.3.e004166.12","first-page":"2225","article-title":"Preliminary core sets for endpoints in ankylosing spondylitis: assessments in ankylosing spondylitis working group","volume":"24","author":"van der Heijde","year":"1997","journal-title":"J Rheumatol"},{"key":"2024072500001072000_10.3.e004166.13","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/rheumatology\/kew238","article-title":"Preliminary core sets for endpoints in ankylosing spondylitis. assessments in ankylosing spondylitis working group","volume":"55","author":"Kiltz","year":"2016","journal-title":"J Rheumatol"},{"key":"2024072500001072000_10.3.e004166.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207544"},{"key":"2024072500001072000_10.3.e004166.15","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6983272","article-title":"Long-term effectiveness of secukinumab in patients with axial spondyloarthritis","volume":"2020","author":"Gentileschi","year":"2020","journal-title":"Mediators Inflamm"},{"key":"2024072500001072000_10.3.e004166.16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10067-020-04944-5","article-title":"Real-world experience of secukinumab treatment for ankylosing spondylitis at the royal national hospital for rheumatic diseases, bath","volume":"39","author":"Williams","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2024072500001072000_10.3.e004166.17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001280","article-title":"Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the Eurospa collaboration","volume":"6","author":"Michelsen","year":"2020","journal-title":"RMD Open"},{"key":"2024072500001072000_10.3.e004166.18","first-page":"260","article-title":"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 stud","volume":"37","author":"Deodhar","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2024072500001072000_10.3.e004166.19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/acr.24517","article-title":"Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis: long\u2010term results of two phase III randomized controlled trials","volume":"74","author":"Kvien","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024072500001072000_10.3.e004166.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5609"},{"key":"2024072500001072000_10.3.e004166.21","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1093\/rheumatology\/keab070","article-title":"Similar biologic drug response regardless of radiographic status in axial Spondyloarthritis: data from the British society for rheumatology biologics register in ankylosing spondylitis registry","volume":"60","author":"Michelena","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024072500001072000_10.3.e004166.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150372"},{"key":"2024072500001072000_10.3.e004166.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.38140"},{"key":"2024072500001072000_10.3.e004166.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202389"},{"key":"2024072500001072000_10.3.e004166.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160958"},{"key":"2024072500001072000_10.3.e004166.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0897-6","article-title":"Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice","volume":"17","author":"Wallman","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2024072500001072000_10.3.e004166.27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002067","article-title":"Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort","volume":"8","author":"Ciurea","year":"2022","journal-title":"RMD Open"},{"key":"2024072500001072000_10.3.e004166.28","unstructured":"EuroSpA . The EuroSpA research collaboration network, Available: https:\/\/eurospa.eu"},{"key":"2024072500001072000_10.3.e004166.29","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/kez427","article-title":"Retention and response rates in 14 261 PSA patients starting TNF inhibitor treatment - results from 12 countries in Eurospa","volume":"59","author":"Brahe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024072500001072000_10.3.e004166.30","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","article-title":"Treatment response and drug retention rates in 24 195 biologic-na\u00efve patients with axial spondyloarthritis initiating Tnfi treatment: routine care data from 12 registries in the Eurospa collaboration","volume":"78","author":"\u00d8rnbjerg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024072500001072000_10.3.e004166.31","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/acr.24560","article-title":"Real-world six- and twelve-month drug retention, remission, and response rates of secukinumab in 2,017 patients with psoriatic arthritis in thirteen European countries","volume":"74","author":"Michelsen","year":"2022","journal-title":"Arthritis Care & Research"},{"key":"2024072500001072000_10.3.e004166.32","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"2024072500001072000_10.3.e004166.33","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2024072500001072000_10.3.e004166.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"2024072500001072000_10.3.e004166.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.21570"},{"key":"2024072500001072000_10.3.e004166.36","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i05"},{"key":"2024072500001072000_10.3.e004166.37","unstructured":"Team RC . R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2022."},{"key":"2024072500001072000_10.3.e004166.38","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/acr.24523","article-title":"One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis: results from five nordic biologic registries including more than 10,000 treatment courses","volume":"74","author":"Glintborg","year":"2022","journal-title":"Arthritis Care & Research"},{"key":"2024072500001072000_10.3.e004166.39","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1093\/rheumatology\/keac174","article-title":"The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis","volume":"61","author":"Nissen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024072500001072000_10.3.e004166.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220097"},{"key":"2024072500001072000_10.3.e004166.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02613-9","article-title":"Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, prevent","volume":"23","author":"Braun","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2024072500001072000_10.3.e004166.42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.125526"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T19:03:05Z","timestamp":1721934185000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/rmdopen-2024-004166"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004166","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}